CIRIUM
24.1.2023 09:01:33 CET | Business Wire | Press release
The new Cirium Fleet Forecast reveals demand for approximately 44,500 new aircraft globally over the next two decades, worth US$2.9 trillion.
The forecast published by Ascend by Cirium, the consultancy arm of aviation analytics firm Cirium, is an independent outlook of the global passenger and freighter market for the next 20 years.
It reaffirms an encouraging long-term projection for the aviation industry and its recovery from the Covid-19 pandemic, predicting that 20-year aircraft deliveries will be 1% lower globally than predicted a year ago.
This comes despite Russia’s invasion of Ukraine, travel restrictions in China, and rising energy costs all emerging as influential factors during 2022.
The aviation industry’s recovery from the Covid-19 crisis in early 2020, has progressed significantly if unevenly across regions. Global aviation activity is predicted to reach 2019 levels in October.
Rob Morris, Ascend by Cirium’s Global Head of Consultancy, said: “The new Cirium Fleet Forecast shows a positive long-term outlook for aviation. The industry is undergoing structural changes but remains on course to return to traditional growth paths by 2025.”
“The global passenger fleet will be required to increase by around 22,000 aircraft to service passenger traffic, which we predict to grow 3.6% annually to reach 47,700 aircraft by the end of 2041.
“These new aircraft will be required to meet demand for air travel, but also to replace less efficient, older-generation types.”
Asia will account for over 40% of new deliveries
Asia-Pacific remains the key growth region for new deliveries, driven by China. The country is forecast to have the highest annual passenger traffic growth rate at over 6% and account for 19% of deliveries in 2041, ahead of all other Asia-Pacific countries, with a combined share of 22%.
North American and European airlines are projected to account for 21% and 17% of deliveries respectively. Middle East airlines will take 7% of deliveries, accounting for 14% in value terms due to the rich mix of higher value twin-aisle deliveries.
In the forecast, Russian capacity and traffic are assumed to decline in the near term. Combined with the complete cessation of Ukrainian civil aviation activity, Russia/CIS traffic is then forecast to stabilize at 70% of 2019 levels in 2024.
Demand for single-aisles will drive fleet growth
At the end of November 2022, the single-aisle fleet was within 2% of 2019 levels, but twin-aisle aircraft numbers were still down by 20%. The single-aisle fleet will grow faster by 3.7% annually, against 3.2% for twin-aisles as the recovery of long-haul traffic continues to lag. The regional aircraft fleet will rise more modestly, by 1.1% a year, with the turboprop fleet set to grow at a faster rate within the regional sector.
Forecast traffic growth over the long term will require the global passenger fleet to increase by around 22,000 aircraft, which equates to a 3.1% annual growth rate, taking the inventory to some 47,700 aircraft at the end of 2041.
The in-service passenger fleet is not forecast to return to 2019 levels until mid-2023, thus effectively losing up to four years of ‘normal’ fleet growth.
Airbus and Boeing will remain the two largest commercial aircraft OEMs, delivering an estimated 80% of aircraft between them and 88% by value through 2041. However, there is US$360 billion of demand for other OEMs or new programs.
The pressures to replace older, less-efficient types will increase
Close to 88% of the current passenger fleet is forecast to be retired from passenger service during the next 20 years. Freighters have longer useful economic lives, so approximately 70% of the current fleet will be retired by 2041.
Overall, there will be some 19,000 retirements from the end-2021 passenger fleet, plus a further 2,500 aircraft that leave the passenger fleet via cargo conversion.
As pressure to switch to more environmentally friendly aircraft grows, replacing less efficient older-generation types will be an increasingly important element of fleet planning. The Covid-19 crisis has seen relatively young aircraft being phased out, while those of older vintages may remain in storage until eventual scrapping.
The freighter boom continues, but may not persist
Freight capacity (available tonne kilometres or ATKs) is forecast to grow annually at 3.0% and traffic (FTKs) at 3.7%, relative to 2019. The forecast predicts the supply of some 3,560 freighter aircraft over the next 20 years, including 1,060 new builds (30%) worth US$130 billion, and 2,480 conversions of passenger aircraft (70%).
This is a similar volume and profile to that predicted in the previous forecast, reflecting the continued near-term boom in conversions triggered by the air-cargo market dynamics of the Covid-19 pandemic, including a short-term drop in passenger belly capacity, e-commerce growth and rising feedstock availability. Although the current conversion boom may not persist, it is enabling the replacement of older, less efficient aircraft.
To download an executive summary of the Cirium Fleet Forecast, [click here]
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005195/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
